EDAP TMS ( (EDAP) ) has provided an announcement.
EDAP TMS reported record financial results for 2024, with a 15.3% increase in full-year HIFU revenue and a 51% growth in U.S. Focal One HIFU procedures. The company received CE Mark certification for treating deep infiltrating endometriosis and published positive outcomes from the HIFI study, which may reshape prostate cancer treatment. Recent strategic appointments to the Board of Directors and advancements in clinical trials underscore EDAP’s commitment to expanding its market presence and enhancing shareholder value.
More about EDAP TMS
EDAP TMS is a global leader in robotic energy-based therapies, specializing in High-Intensity Focused Ultrasound (HIFU) technology. The company focuses on providing innovative treatment solutions for prostate cancer and is expanding its applications to other areas such as endometriosis, benign prostatic hyperplasia (BPH), and pancreatic cancer.
YTD Price Performance: -14.58%
Average Trading Volume: 80,989
Technical Sentiment Signal: Buy
Current Market Cap: $76.06M
Find detailed analytics on EDAP stock on TipRanks’ Stock Analysis page.